A new drug (compound 445) has been shown to increase proteosome-mediated degradation of occludin-1, a tight junction molecule. It has been shown to have some benefit in patients with neurological autoimmune disorders. A patient presents with EEEV infection in the clinic and the doctor proposes compound 445 as an experimental treatment to prevent severe neurological disease. What do you predict would be the outcome of this course of treatment?
a. None of these
b. 445 treatment leads to decreased viral titer in the brain and better patient outcome
c. 445 treatment leads to decreased viral titer in the brain and worse disease
d. 445 treatment leads to increased viral titer in the brain and worse disease
e. 445 treatment leads to increased viral titer in the brain and better patient outcome